86
Participants
Start Date
June 30, 2014
Primary Completion Date
February 29, 2016
Study Completion Date
October 31, 2016
Ruxolitinib
5 mg tablets to be administered by mouth twice daily (BID)
Placebo
5 mg matching placebo tablets to be administered by mouth twice daily (BID)
Capecitabine
150 mg or 500 mg tablets to be administered by mouth twice daily (BID)
Huntsville
Fayetteville
Beverly Hills
La Jolla
Aurora
Denver
Washington D.C.
Fort Myers
St. Petersburg
Athens
Atlanta
Macon
Thomasville
Harvey
Indianapolis
Kansas City
Louisville
Baltimore
Boston
Farmington Hills
Kalamazoo
Lansing
Minneapolis
Saint Louis Park
Bolivar
Basking Ridge
Cherry Hill
Voorhees Township
Commack
Fresh Meadows
Harrison
New York
Rochester
Rockville Centre
Sleepy Hollow
Canton
Cincinnati
Portland
Allentown
Hershey
Langhorne
Greenville
Chattanooga
Knoxville
Nashville
Dallas
Fort Worth
Lubbock
San Antonio
Temple
Salt Lake City
Falls Church
Newport News
Seattle
Green Bay
Graz
Linz
Salzburg
Vienna
Wein
Santiago
Vitacura
Bogotá
Medellín
Næstved
Odense C
Bordeaux
Brest
Dijon
Lyon
Nancy
Cork
Dubin
Galway
Beersheba
Haifa
Jerusalem
Petah Tikva
Ramat Gan
Tel Aviv
Tel Litwinsky
Monterrey
Oaxaca City
Toluca
Amsterdam
Maastricht
Nijmegen
Braga
Lisbon
Porto
San Juan
Linköping
Uppsala
Bellinzona
Geneva
Lead Sponsor
Incyte Corporation
INDUSTRY